This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effects of Propofol and Isoflurane on Pulmonary Vascular Resistance

This study has been completed.
Information provided by (Responsible Party):
Michelle White, University Hospitals Bristol NHS Trust Identifier:
First received: November 4, 2009
Last updated: December 14, 2011
Last verified: December 2011
The investigators hypothesize that there is no difference between the effects of isoflurane and propofol anaesthesia on pulmonary vascular resistance (PVR).

Condition Intervention Phase
Hypertension, Pulmonary Drug: propofol and isoflurane Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Diagnostic
Official Title: Randomised Cross-over Pilot Study to Determine the Effects of Isoflurane and Propofol on Pulmonary Vascular Resistance in Children With Pulmonary Hypertension.

Resource links provided by NLM:

Further study details as provided by Michelle White, University Hospitals Bristol NHS Trust:

Primary Outcome Measures:
  • The primary endpoint is the percentage change in PVR under isoflurane anaesthesia compared with propofol anaesthesia. [ Time Frame: 2 hours ]

Secondary Outcome Measures:
  • The secondary endpoints are the percentage change in mean pulomanry artery pressure (PAP), systemic vascular resistance (SVR) and mean arterial pressure (MAP). [ Time Frame: 2 hours ]

Enrollment: 10
Study Start Date: November 2009
Study Completion Date: December 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: propofol and isoflurane
    both drugs administered at age-related dose and titrated to effect. maximum dose of propofol 15 mg/kg/hr, maximum dose of isoflurane 1.5 MAC

Ages Eligible for Study:   3 Months to 16 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All children between 3 months and 16 years of age with pulmonary arterial hypertension undergoing a PVR study.

Exclusion Criteria:

  • Children with a known adverse reaction to one of the study drugs eg malignant hyperpyrexia or a disorder of fatty acid oxidation.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01212523

United Kingdom
UH bristol NHS Trust
Bristol, United Kingdom, BS2 8BJ
Sponsors and Collaborators
University Hospitals Bristol NHS Foundation Trust
  More Information

Responsible Party: Michelle White, Consultant in Paediatric Anaesthesia and Critical Care, University Hospitals Bristol NHS Trust Identifier: NCT01212523     History of Changes
Other Study ID Numbers: CH/2007/2476
2009-010614-30 ( Registry Identifier: EudraCT )
Study First Received: November 4, 2009
Last Updated: December 14, 2011

Keywords provided by Michelle White, University Hospitals Bristol NHS Trust:
pulmonary hypertension
congenital heart disease

Additional relevant MeSH terms:
Hypertension, Pulmonary
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
Anesthetics, Intravenous
Anesthetics, General
Anesthetics, Inhalation processed this record on September 21, 2017